Research ArticleOriginal Article
Open Access

Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial

Shuzhen Lai, Peijing Li, Xiaohui Liu, Guihong Liu, Tieming Xie, Xing Zhang, Xiaoxuan Wang, Jing Huang, Yiqiang Tang, Zhigang Liu, Guoping Shen, Chaoming Li, Fangxiao Lu, Lei Wang, Fagui Jiang, Caixing Sun, Yuanyuan Chen and Ming Chen
Cancer Biology & Medicine May 2024, 21 (5) 433-444; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0373

References

  1. 1.↵
    2. Ostrom QT,
    3. Cioffi G,
    4. Gittleman H,
    5. Patil N,
    6. Waite K,
    7. Kruchko C, et al.
    CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019; 21: v1–100.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Zhang K,
    3. Liu X,
    4. Li G,
    5. Chang X,
    6. Li S,
    7. Chen J, et al.
    Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011-2017): a multicenter retrospective study from CGGA. Cancer Biol Med. 2022; 19: 1460–76.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    2. Xu C,
    3. Yuan X,
    4. Hou P,
    5. Li Z,
    6. Wang C,
    7. Fang C, et al.
    Development of glioblastoma organoids and their applications in personalized therapy. Cancer Biol Med. 2023; 20: 353–68.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    2. Cui X,
    3. Wang Y,
    4. Zhou J,
    5. Wang Q,
    6. Kang C.
    Expert opinion on translational research for advanced glioblastoma treatment. Cancer Biol Med. 2023; 20: 344–52.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Stupp R,
    3. Mason WP,
    4. van den Bent MJ,
    5. Weller M,
    6. Fisher B,
    7. Taphoorn MJ, et al.
    Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987–96.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    2. Furnari FB,
    3. Fenton T,
    4. Bachoo RM,
    5. Mukasa A,
    6. Stommel JM,
    7. Stegh A, et al.
    Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21: 2683–710.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    2. Jain RK,
    3. di Tomaso E,
    4. Duda DG,
    5. Loeffler JS,
    6. Sorensen AG,
    7. Batchelor TT.
    Angiogenesis in brain tumours. Nat Rev Neurosci. 2007; 8: 610–22.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Gilbert MR,
    3. Dignam JJ,
    4. Armstrong TS,
    5. Wefel JS,
    6. Blumenthal DT,
    7. Vogelbaum MA, et al.
    A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370: 699–708.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    2. Chinot OL,
    3. Wick W,
    4. Mason W,
    5. Henriksson R,
    6. Saran F,
    7. Nishikawa R, et al.
    Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370: 709–22.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    2. Mellinghoff IK,
    3. Lassman AB,
    4. Wen PY.
    Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia. 2011; 59: 1205–12.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. Lee EQ,
    3. Kaley TJ,
    4. Duda DG,
    5. Schiff D,
    6. Lassman AB,
    7. Wong ET, et al.
    A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients. Clin Cancer Res. 2015; 21: 3610–8.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    2. Hottinger AF,
    3. Ben Aissa A,
    4. Espeli V,
    5. Squiban D,
    6. Dunkel N,
    7. Vargas MI, et al.
    Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer. 2014; 110: 2655–1.
    OpenUrl
  13. 13.↵
    2. Shen G,
    3. Zheng F,
    4. Ren D,
    5. Du F,
    6. Dong Q,
    7. Wang Z, et al.
    Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018; 11: 120.
    OpenUrlPubMed
  14. 14.↵
    2. Sun X,
    3. Zhang R,
    4. Xu J,
    5. Xie L,
    6. Guo W.
    First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: a prospective, single-arm trial. Asia Pac J Trop Med. 2022; 15: 266–73.
    OpenUrl
  15. 15.↵
    2. Jiang S,
    3. Liang H,
    4. Liu Z,
    5. Zhao S,
    6. Liu J,
    7. Xie Z, et al.
    The Impact of anlotinib on brain metastases of non-small cell lung cancer: post hoc analysis of a phase III randomized control trial (ALTER0303). Oncologist. 2020; 25: e870–4.
    OpenUrl
  16. 16.↵
    2. Li PJ,
    3. Lai SZ,
    4. Jin T,
    5. Ying HJ,
    6. Chen YM,
    7. Zhang P, et al.
    Radiotherapy opens the blood-brain barrier and synergizes with anlotinib in treating glioblastoma. Radiother Oncol. 2023; 183: 109633.
  17. 17.↵
    2. Garcia J,
    3. Hurwitz HI,
    4. Sandler AB,
    5. Miles D,
    6. Coleman RL,
    7. Deurloo R, et al.
    Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020; 86: 102017.
  18. 18.↵
    2. Louis DN,
    3. Perry A,
    4. Reifenberger G,
    5. von Deimling A,
    6. Figarella-Branger D,
    7. Cavenee WK, et al.
    The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131: 803–20.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Lai Z,
    3. Markovets A,
    4. Ahdesmaki M,
    5. Chapman B,
    6. Hofmann O,
    7. McEwen R, et al.
    VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016; 44: e108.
  20. 20.↵
    2. Li Q,
    3. Wang K.
    InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP Guidelines. Am J Hum Genet. 2017; 100: 267–80.
    OpenUrlPubMed
  21. 21.↵
    2. Talevich E,
    3. Shain AH,
    4. Botton T,
    5. Bastian BC.
    CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016; 12: e1004873.
  22. 22.↵
    2. Newman AM,
    3. Bratman SV,
    4. Stehr H,
    5. Lee LJ,
    6. Liu CL,
    7. Diehn M, et al.
    FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics. 2014; 30: 3390–3.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Curran WJ Jr.,
    3. Scott CB,
    4. Horton J,
    5. Nelson JS,
    6. Weinstein AS,
    7. Fischbach AJ, et al.
    Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85: 704–10.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    2. Brandes AA,
    3. Franceschi E,
    4. Paccapelo A,
    5. Tallini G,
    6. De Biase D,
    7. Ghimenton C, et al.
    Role of MGMT methylation status at time of diagnosis and recurrence for patients with glioblastoma: clinical implications. Oncologist. 2017; 22: 432–7.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    2. Berger MF,
    3. Mardis ER.
    The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018; 15: 353–65.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Sandmann T,
    3. Bourgon R,
    4. Garcia J,
    5. Li C,
    6. Cloughesy T,
    7. Chinot OL, et al.
    Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol. 2015; 33: 2735–44.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    2. Zhao YR,
    3. Wang JL,
    4. Xu C,
    5. Li YM,
    6. Sun B,
    7. Yang LY.
    HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling. Clin Sci (Lond). 2019; 133: 1645–62.
    OpenUrlCrossRef
  28. 28.↵
    2. Álvarez-Satta M,
    3. Matheu A.
    Primary cilium and glioblastoma. Ther Adv Med Oncol. 2018; 10: 1758835918801169.
  29. 29.↵
    2. Goranci-Buzhala G,
    3. Mariappan A,
    4. Ricci-Vitiani L,
    5. Josipovic N,
    6. Pacioni S,
    7. Gottardo M, et al.
    Cilium induction triggers differentiation of glioma stem cells. Cell Rep. 2021; 36: 109656.
  30. 30.↵
    2. Li D,
    3. Chi Y,
    4. Chen X,
    5. Ge M,
    6. Zhang Y,
    7. Guo Z, et al.
    Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial. Clin Cancer Res. 2021; 27: 3567–75.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    2. Sugita K,
    3. Kawakami K,
    4. Yokokawa T,
    5. Mae Y,
    6. Toya W,
    7. Hagino A, et al.
    Investigation of regorafenib-induced hypothyroidism in patients with metastatic colorectal cancer. Anticancer Res. 2015; 35: 4059–62.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    2. Patel S,
    3. Dushenkov A,
    4. Jungsuwadee P,
    5. Krishnaswami A,
    6. Barac A.
    Team-based approach to management of hypertension associated with angiogenesis inhibitors. J Cardiovasc Transl Res. 2020; 13: 463–77.
    OpenUrl
  33. 33.↵
    2. Lai A,
    3. Tran A,
    4. Nghiemphu PL,
    5. Pope WB,
    6. Solis OE,
    7. Selch M, et al.
    Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011; 29: 142–8.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords